vcn-01
vcn-01: sourced relationships with 1 company · 2 clinical trials tracked.
vcn-01 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could vcn-01 → TOVX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Theriva Biologics, Inc. (TOVX) | Phase 2 |
Clinical Trial Registry Records (2)
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Primary endpoint: Overall Survival
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
Primary endpoint: Type, frequency, severity, and attribution of AEs/SAEs as assessed by CTCAE v 5.0
Frequently asked questions
Which companies have sourced relationships with vcn-01?
vcn-01 has dated SEC/FDA relationship records for Theriva Biologics, Inc..
How many clinical trials involve vcn-01?
BioSniper tracks 2 clinical trials involving vcn-01.